Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma-Reference-Cited by-同舟云学术

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma

Published:2012-11 Issue:16 Volume:48 Page:2983-2992
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Blayney Jaine K.,Ceresoli Giovanni L.,Castagneto Bruno,O’Brien Mary E.R.,Hasan Baktiar,Sylvester Richard,Rudd Robin,Steele Jeremy,Busacca Sara,Porta Camillo,Mutti Luciano,O’Byrne Kenneth J,Scullin Paula,Gaafar Rabab,Baas Paul,Van Meerbeeck Jan,Fennell Dean A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Advances in the systemic therapy of malignant pleural mesothelioma;Fennell;Nat Clin Pract Oncol,2008

2. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development;Fennell;Lancet Oncol,2004

3. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992);Baas;Eur J Cancer,2003

4. Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

5. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial;Muers;Lancet,2008

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma;The Lancet Respiratory Medicine;2024-06

2. Epigenomics in Malignant Pleural Mesothelioma;Mesothelioma - Diagnostics, Treatment and Basic Research;2022-12-21

3. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial;Lung Cancer;2022-07

4. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study;The Lancet Oncology;2022-06

5. Abemaciclib for malignant pleural mesothelioma – Authors' reply;The Lancet Oncology;2022-06